These data suggest that 60% of malignant pleural mesothelioma patients …present an attractive candidate for cancer immunotherapeutic options.
RALEIGH, N.C. (PRWEB)
November 08, 2017
A study conducted by researchers in Italy and at Genentech finds that six out of ten mesothelioma patients may have a genetic makeup that makes them good candidates for immunotherapy. Surviving Mesothelioma has the full story. Click here to read it now.
In a study of 99 mesothelioma tumor samples, cancer researchers at San Luigi Hospital in Torino and Antonio and Biagio General Hospital in Alessandria discovered that some of them expressed certain immune-related genes that could put the odds in their favor with immunotherapy.
“These data suggest that 60% of malignant pleural mesothelioma patients characterized by either PD-L1 expression or an inflamed status present an attractive candidate for cancer immunotherapeutic options,” writes lead researcher Namrata Patil with California-based biotech company, Genentech.
The study in the Journal of Thoracic Oncology utilized a testing tool called NanoString to test for 800 different genes in mesothelioma tumor cells and in their infiltrating immune system cells.
“Immunotherapy is widely recognized to be one of the most promising approaches to intractable cancers like pleural mesothelioma,” says Alex Strauss, Managing Editor for Surviving Mesothelioma. “But for it to be most effective, doctors need a method for selecting the best patients.”
To read more about the new study on mesothelioma immunotherapy, see Immunotherapy for Mesothelioma: Who Are the Best Candidates?, now available on the Surviving Mesothelioma website.
Patil, NS, et al, “Molecular and Histopathological…